Clinical trials
Recurrent High Grade B-Cell Lymphoma clinical trials
Below are recruiting recurrent high grade b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 68 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT07365306RecruitingPhase 2
Epcoritamab with chemo before stem cell transplant for DLBCL
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Duarte, CaliforniaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06209619RecruitingPhase 1
Study of CC-99282 plus rituximab after CAR-T for lymphoma
This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.
Columbus, OhioAges 18 years+ - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT07606937RecruitingEarly Phase 1
Automated CAR-T cell therapy for relapsed large B-cell lymphoma
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT06618313Recruiting
Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
BeijingAges 18 years+ - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+ - NCT06045247RecruitingPhase 2
Epcoritamab with low-intensity chemo for older or frail patients with new lymphoma
This study tests a new immunotherapy drug (epcoritamab) combined with a milder chemotherapy (rituximab-mini CVP) for older or frail patients who cannot receive standard strong chemo. It aims to effectively treat newly diagnosed diffuse large B-cell lymphoma with fewer side effects.
Houston, TexasAges 18 years+ - NCT06321289RecruitingPhase 1/Phase 2
Donor T cell therapy for B-cell lymphoma
This trial tests a new type of therapy where specially designed donor T cells target your lymphoma. It's for people with certain B-cell non-Hodgkin lymphomas that have not responded to or returned after standard treatments. You might join if you meet the health and disease criteria listed below.
Beijing, Beijing MunicipalityAges 18–75 - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Huntington Park, CaliforniaAges 18 years+ - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT03418038RecruitingPhase 2
Vitamin C with chemotherapy for certain relapsed blood cancers
This Phase 2 trial tests whether intravenous vitamin C (ascorbic acid) added to chemotherapy can improve outcomes for people with certain relapsed or treatment-resistant lymphomas or chronic myelomonocytic leukemia (CMML). It may help by boosting chemotherapy’s effectiveness and/or changing how the cancer responds.
Mankato, MinnesotaAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05432635RecruitingPhase 1
CAR T-cell and vaccine treatment after stem cell transplant
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
Duarte, CaliforniaAges 18 years+
Hear when a new Recurrent High Grade B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent high grade b-cell lymphoma?
- Yes. Clin2 currently lists 68 recruiting recurrent high grade b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent high grade b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent high grade b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- High-grade B-cell Lymphoma
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory High Grade B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Recurrent Grade 3b Follicular Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.